Cargando…

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma

PURPOSE: The contemporary management of early-stage Hodgkin lymphoma (ES-HL) involves balancing the risk of late adverse effects of radiotherapy against the increased risk of relapse if radiotherapy is omitted. This study provides information on the risk of radiation-related cardiovascular disease t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cutter, David J., Ramroth, Johanna, Diez, Patricia, Buckle, Andy, Ntentas, Georgios, Popova, Bilyana, Clifton-Hadley, Laura, Hoskin, Peter J., Darby, Sarah C., Radford, John, Illidge, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577686/ https://www.ncbi.nlm.nih.gov/pubmed/34388007 http://dx.doi.org/10.1200/JCO.21.00408

Ejemplares similares

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
por: Shakir, Rebecca, et al.
Publicado: (2022)

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
por: Shakir, Rebecca, et al.
Publicado: (2022)

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

Cancer Informatics in the U.K.: The NCRI Informatics Initiative
por: Reddington, Fiona, et al.
Publicado: (2007)

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
por: Ntentas, Georgios, et al.
Publicado: (2019)

P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
por: Geurts, Yvonne M.G., et al.
Publicado: (2022)

Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection
por: Ntentas, Georgios, et al.
Publicado: (2022)

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
por: Houlihan, Orla A., et al.
Publicado: (2022)

Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma
por: Geurts, Yvonne M., et al.
Publicado: (2023)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Highlights of the twelfth annual meeting of the National Cancer Research Institute (NCRI), 6–9 November 2016, Liverpool, UK
por: Cairns, Linda, et al.
Publicado: (2017)

Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial
por: Gleeson, M., et al.
Publicado: (2017)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
por: Freeman, Sylvie D., et al.
Publicado: (2023)

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial()
por: McMillan, A.K., et al.
Publicado: (2020)

Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
por: Kasamon, Yvette L.
Publicado: (2011)

Cardiovascular disease incidence rates: a study using routinely collected health data
por: Ramroth, Johanna, et al.
Publicado: (2023)

The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma
por: Eslick, R, et al.
Publicado: (2017)

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
por: Burnett, Alan K, et al.
Publicado: (2018)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
por: Townsend, William, et al.
Publicado: (2019)

Selected Abstracts from the 2018 NCRI Cancer Conference of National Cancer Research Institute
Publicado: (2018)

Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute
Publicado: (2019)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz, Carminia, et al.
Publicado: (2018)

Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin’s lymphoma
por: Kim, Yu Ri, et al.
Publicado: (2021)

Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
por: Jennane, Selim, et al.
Publicado: (2022)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018)

Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study
por: Snowden, John A., et al.
Publicado: (2022)

ncRI: a manually curated database for experimentally validated non-coding RNAs in inflammation
por: Wang, Shuyuan, et al.
Publicado: (2020)

Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study
por: Parsons, Susan K., et al.
Publicado: (2023)

The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma
por: Seth, Rachna, et al.
Publicado: (2012)

Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
por: Huntington, Scott F, et al.
Publicado: (2019)

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors
por: Cooke, R, et al.
Publicado: (2013)

Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group
por: Cerci, Juliano Júlio, et al.
Publicado: (2018)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma
por: Shelly, M. J., et al.
Publicado: (2012)

Relationship between semiquantitative (18)F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
por: Kahle, X. U., et al.
Publicado: (2019)

Positron emission tomography
Publicado: (1995)

Positron Emission Tomography
por: Piepmeier, Joseph M.
Publicado: (1986)

Positron emission tomography
por: Paans, A M J
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_r0a2jnveg0gsb35mnu4gtfj977